Level Bio's earnings have been declining at an average annual rate of -43.3%, while the Life Sciences industry saw earnings growing at 4.4% annually. Revenues have been declining at an average rate of 6.7% per year.
Key information
-43.29%
Earnings growth rate
-43.30%
EPS growth rate
Life Sciences Industry Growth
26.83%
Revenue growth rate
-6.65%
Return on equity
-613.68%
Net Margin
-8.56%
Last Earnings Update
31 Mar 2026
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Level Bio makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
DB:4MB Revenue, expenses and earnings (SEK Millions)
Date
Revenue
Earnings
G+A Expenses
R&D Expenses
31 Mar 26
34
-3
18
0
31 Dec 25
32
-4
18
0
30 Sep 25
30
-4
18
0
30 Jun 25
30
-5
18
0
31 Mar 25
27
-6
19
0
31 Dec 24
25
-8
20
0
30 Sep 24
24
-11
20
0
30 Jun 24
24
-12
22
0
31 Mar 24
23
-11
21
0
31 Dec 23
26
-9
20
0
30 Sep 23
30
-5
19
0
30 Jun 23
29
-4
16
0
31 Mar 23
30
-4
16
0
31 Dec 22
34
-2
16
0
30 Sep 22
36
-2
16
0
30 Jun 22
38
-1
21
0
31 Mar 22
48
5
16
0
31 Dec 21
44
5
12
0
30 Sep 21
38
5
15
0
30 Jun 21
36
5
8
0
31 Mar 21
27
2
8
0
31 Dec 20
24
2
8
0
30 Sep 20
22
1
8
0
30 Jun 20
21
1
8
0
31 Mar 20
20
0
8
0
31 Dec 19
17
-1
8
0
30 Sep 19
18
-1
9
0
30 Jun 19
19
-1
9
0
31 Mar 19
18
-1
9
0
31 Dec 18
18
-1
9
0
30 Sep 18
18
-1
11
0
30 Jun 18
18
-2
11
0
31 Mar 18
20
-3
11
0
31 Dec 17
23
-1
11
0
30 Sep 17
26
0
9
0
30 Jun 17
30
1
9
0
31 Mar 17
29
2
9
0
31 Dec 16
27
1
9
0
30 Sep 16
26
1
9
0
30 Jun 16
24
1
9
0
31 Mar 16
24
1
9
0
31 Dec 15
24
1
9
0
30 Sep 15
22
0
8
0
Quality Earnings: 4MB is currently unprofitable.
Growing Profit Margin: 4MB is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4MB is unprofitable, and losses have increased over the past 5 years at a rate of 43.3% per year.
Accelerating Growth: Unable to compare 4MB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 4MB is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (8.5%).
Return on Equity
High ROE: 4MB has a negative Return on Equity (-613.68%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/07/13 12:55
End of Day Share Price
2026/07/10 00:00
Earnings
2026/03/31
Annual Earnings
2025/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Level Bio AB (publ) is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.